Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anti-human CD19 T-cell injection in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20211909Phase 2Active
- Sponsor
- Hengrun Dasheng
- Start
- Oct 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of DASH CD19 CAR-T in mature B-cell lymphoma, sponsored by Hengrun Dasheng. Started Oct 2021; status: active.
02
Drugs
DASH CD19 CAR-T
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20211909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211909.